Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors
- 10 July 2024
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (3) , 768-779
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- National Cancer Institute (P50CA247749)
- National Cancer Institute (P30 CA008)
- Merck
- National Institutes of Health
This publication has 50 references indexed in Scilit:
- Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerBreast Cancer Research and Treatment, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancerThe Journal of Pathology, 2017
- Signatures of mutational processes in human cancerNature, 2013
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- The Life History of 21 Breast CancersCell, 2012
- Homologous Recombination Assay for Interstrand Cross-Link Repair2011
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual dataThe Lancet, 2000
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999